

SANOFI-AVENTIS
Form 6-K
July 10, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2007

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In July 2007, sanofi-aventis issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated July 8, 2007: New study shows that extending prophylaxis with Clexane® / Lovenox® (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobility.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 10, 2007

SANOFI-AVENTIS

By: /S/ Patricia Kodyra
Name: Patricia Kodyra
Title: Associate Vice President
Financial and Securities Law

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated July 8, 2007: New study shows that extending prophylaxis with Clexane [®] / Lovenox [®] (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobility.